Table 2.

Odds ratio analysis of the risk of significant bone loss (α-BMD <−1%) or chance of significant gain in BMD (α-BMD >1%) calculated for the three study populations.1

StudyCutoffOdds ratio of α-BMD <−1% when change is lower than cutoff95% confidence intervalOdds ratio of α-BMD >1% when change is higher than cutoff95% confidence interval
Tibolone
Serum−25.4%24.02.5–22833.36.3–177
Urine−36.8%7.71.3–46.941.07.6–220
Ibandronate
Serum−54.9%6.31.3–31.23.81.4–10.1
Urine−52.8%22.12.7–1826.72.4–19.0
HRT
Serum−27.8%>10012.45.0–31.2
Urine−41.2%22.73.4–22211.04.4–27.9